CINCINNATI, June 20, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today two new ...

VANCOUVER, British Columbia -- The novel multitarget stool RNA test (ColoSense) showed high sensitivity for detecting colorectal neoplasia among adults ages 45 and older, according to the phase III ...

ST. LOUIS--(BUSINESS WIRE)--Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, announced the publication of a ...

Please provide your email address to receive an email when new articles are posted on . Previously granted FDA breakthrough device designation in January 2020, ColoSense is the “first noninvasive ...

About The Study: In a clinical trial that included 8,920 participants, a noninvasive, multitarget stool RNA test (ColoSense) for colorectal cancer screening showed high sensitivity for colorectal ...

The NCCN Guidelines are comprehensive, evidence-based recommendations to support the prevention, diagnosis, and treatment of more than 97% of cancers affecting patients in the United States. They are ...

VANCOUVER, BC — Two multitarget stool tests in development compare favorably for colorectal cancer (CRC) screening in average-risk people, suggest two new studies. In a blinded, prospective, ...

A study has used advanced genetic and genomic techniques to offer a major step forward in understanding and diagnosing infectious intestinal diseases. The large-scale study analyzed more than 1,000 ...